Molnupiravir: is it time to move in or move out?
NE Castillo Almeida, AC Kalil - NEJM evidence, 2022 - evidence.nejm.org
Molnupiravir: Is It Time to Move In or Move Out? With more than 250 million diagnosed
cases and 5 million deaths, Covid-19 is our epoch-defining pandemic—and it is still …
cases and 5 million deaths, Covid-19 is our epoch-defining pandemic—and it is still …
What will be the role of molnupiravir in the treatment of COVID-19 infection?
A Vitiello, V Troiano, R La Porta - Drugs & Therapy Perspectives, 2021 - Springer
The global COVID-19 pandemic is currently underway. To date, there are approximately
4.55 million deaths and 219 million people infected [1]. The massive vaccination campaign …
4.55 million deaths and 219 million people infected [1]. The massive vaccination campaign …
[HTML][HTML] The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review
Background Throughout the time of the global pandemic of SARS-CoV-2 virus, there has
been a compelling necessity for the development of effective antiviral agents and …
been a compelling necessity for the development of effective antiviral agents and …
Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients
A Jayk Bernal, MM Gomes da Silva… - … England Journal of …, 2022 - Mass Medical Soc
Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …
Molnupiravir: An antiviral drug against COVID-19
Abstract SARS-CoV-2, the virus responsible for COVID-19, has caused numerous deaths
worldwide and poses significant challenges. Researchers have recently studied a new …
worldwide and poses significant challenges. Researchers have recently studied a new …
Molnupiravir—a novel oral anti-SARS-CoV-2 agent
Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral …
rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral …
Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19
GR Painter, MG Natchus, O Cohen, W Holman… - Current opinion in …, 2021 - Elsevier
Highlights•Molnupiravir is a broad acting, oral antiviral versus SARS-CoV-2, flu, Ebola and
others.•Clinical development was greatly accelerated in response to the COVID19 …
others.•Clinical development was greatly accelerated in response to the COVID19 …
Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta-analysis of 14 randomized trials with 34 570 patients–authors' response
M Sun, H Lai, Z Zhang, L Ge - Journal of Antimicrobial …, 2023 - academic.oup.com
We thank Drs Kow, Ramachandram and Hasan for their interest in our review and their
knowledgeable comments. 1 We agree with your thoughtful view that the most important …
knowledgeable comments. 1 We agree with your thoughtful view that the most important …
Molnupiravir: from hope to epic fail?
D Focosi - Viruses, 2022 - mdpi.com
Molnupiravir has been the first oral antiviral authorized for COVID-19 outpatients, reporting
extraordinary sales and preserved in vitro efficacy against Omicron sublineages so far …
extraordinary sales and preserved in vitro efficacy against Omicron sublineages so far …
Molnupiravir: evidence by press release
JA Cave, D Phizackerley - Drug and Therapeutics Bulletin, 2022 - dtb.bmj.com
On 4 November 2021, the Medicines and Healthcare products Regulatory Agency (MHRA)
announced that it had approved molnupiravir (▼ Lagevrio) as the first oral antiviral drug …
announced that it had approved molnupiravir (▼ Lagevrio) as the first oral antiviral drug …